Gedea Biotech is one of 15 finalists in the national Venture Cup final in Lund on September 21. The company advanced after winning Southern Sweden's semifinal in the “Game changer” class. Gedea Biotech, which develops an antibiotic-free local treatment with a completely new mode of action for the treatment of vaginal infections, recently joined the SmiLe life science incubator in Lund.
Gedea Biotech addresses an area of indication for which current treatments usually do not have adequate effect and for which resistance problems are associated with the therapies. Many women suffer from recurrent vaginal infections without being cured.
Gedea Biotech’s substance is safe, naturally occurring, and approved as a food additive. It works in a completely new way by attacking the infection deeper in the tissue. Moreover, it does not kill the infection, but crowds it out – and therefore does not cause resistance.
“In two to three years, we expect to have a CE-approved vaginal tablet for local treatment of fungal infections, the first of its kind that will effectively cure the symptoms and can also be taken for preventive purposes. But it is also effective against bacterial infections and that will be the next indication,” says Annette Säfholm, CEO of Gedea Biotech.
The 15 finalists will present their pitches onstage in front of an audience and jury. The winner will be presented with a free one-year pass for business trips in first class on SJ trains. The national final jury includes Christian Lauritzen from Eicorn, Eva Fors from Google Cloud Nordic, Elisabeth Brevenson founder of Beepsend, Thomas Torounidis from Awa IPro, and Jacob Youssef from Candy People.
“Time after time we receive evidence of the tremendously talented life science entrepreneurs in southern Sweden who win various awards, including this time when Gedea Biotech did a fantastic job in fierce competition,” says Ebba Fåhraeus, CEO at SmiLe Incubator.